The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise (DIMITOS)
Primary Purpose
Type 2 Diabetes, Oxidative Stress, Mitochondrial Reactive Oxygen Species Production
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Glutathione
Placebo
Sponsored by

About this trial
This is an interventional basic science trial for Type 2 Diabetes focused on measuring type 2 diabetes, mitochondrial reactive oxygen species production, oxidative stress, antioxidant treatment, glutathione supplementation
Eligibility Criteria
Inclusion Criteria:
For patients with type 2 diabetes:
- Male
- 30-50 years
- BMI: 28-35
- ECG with no evidence of heart disease
- HbA1c > 6.5% (48mmol/mol)
For control subjects:
- Male
- 30-50 years
- BMI: 28-35
- ECG with no evidence of Heart disease
Exclusion Criteria:
For patients with type 2 diabetes::
- Insulin treatment
- Antioxidant supplementation or other dietary supplements
- Cholesterol lowering medicine
For control subjects:
- Antioxidant supplementation or other dietary supplements
- Cholesterol lowering medicine
Sites / Locations
- Xlab, Department of Biomedical Sciences, Faculty Of Health Sciences, University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Control
Glutathione
Arm Description
4 placebo tablets/day (2 in the morning and 2 in the evening)
4 oral GSH tablets/day (2 in the morning and 2 in the evening)
Outcomes
Primary Outcome Measures
Insulin sensitivity
Difference in insulin sensitivity (measured as glucose infusion rate during a hyperinsulinaemic euglycaemic clamp) between patients with type 2 diabetes receiving glutathione supplementation and patients with type 2 diabetes receiving placebo.
Secondary Outcome Measures
Mitochondrial reactive oxygen species production
Difference in the mitochondrial reactive oxygen species production between patients with type 2 diabetes receiving glutathione supplementation and patients with type 2 diabetes receiving placebo.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02948673
Brief Title
The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise
Acronym
DIMITOS
Official Title
The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
May 2016 (undefined)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives: The research focus of the study is the production of reactive oxygen species (ROS) in patients with type 2 diabetes (T2D) in response to glutathione (GSH) supplementation and in response to acute exercise.
Oxidative stress is suggested as a possible causative factor in the pathophysiology of skeletal muscle insulin resistance. GSH is the most abundant endogenous antioxidant in the cell and thus, a crucial protector against oxidative stress and insulin resistance. It has been found that patients with T2D have a decreased level of GSH in plasma and that 1 h GSH infusion improves skeletal muscle glucose uptake by ~25% and the redox environment in patients with T2D. Therefore, we want to investigate the effect of 3 months of GSH supplementation on skeletal muscle insulin sensitivity and mitochondrial ROS production in patients with T2D and healthy controls.
Hypothesis: Oral GSH supplementation will improve skeletal muscle insulin sensitivity in patients with T2D and this effect will be linked to a reduced mitochondrial ROS production in the skeletal muscle.
In contrast to the link between oxidative stress and insulin resistance, ROS produced in response to exercise is an important physiological stimulus as it is suggested to play a key role in the beneficial mitochondrial biogenesis observed in response to training. It has been reported that some patients with T2D have a diminished mitochondrial biogenesis in response to training, but the reason for this defect is not known. We want to investigate the link between exercise-stimulated ROS production and the mitochondrial biogenesis response in patients with T2D and healthy controls in response to acute exercise at two different intensities.
Hypothesis: Considering the pathological condition of T2D skeletal muscle (i.e. high chronic ROS level), we speculate that a lower exercise intensity, leading to a lower exercise-stimulated ROS production is a more optimal stimulus (i.e. not to high) for mitochondrial biogenesis in patients with T2D.
Detailed Description
ROS production in response to glutathione supplementation:
Today, 387 million people worldwide suffer from T2D and this number is expected to increase to 592 million in 2035. Skeletal muscle is responsible for ~75% of the total glucose uptake, making skeletal muscle the quantitatively most important tissue when it comes to insulin resistance (1). It has been suggested that oxidative stress may represent a possible causative factor in the pathophysiology of skeletal muscle insulin resistance. The link between ROS and skeletal muscle insulin resistance has been established both in vitro and in vivo (2, 3), but few studies have actually measured ROS production in skeletal muscle of T2D patients (4-6). Mitochondria are a source of ROS, and also a major target of oxidative damage (7). The mitochondrial defense system against oxidative stress relies on endogenous antioxidants. Glutathione (GSH) is the most abundant endogenous antioxidant in the cell and thus, a crucial protector against oxidative stress and insulin resistance (8). Supporting this, patients with T2D have a decreased level of GSH and an increased level of oxidized GSH (GSSG) in plasma (9) and insulin resistant subjects are reported to have an increased mitochondrial ROS production as well as a reduced GSH/GSSG ratio in skeletal muscle compared to healthy controls (3). In addition, 1 h glutathione infusion has been found to increase glucose uptake in patients with T2D by ~25% and to improve the redox environment, as reflected by an increased GSH/GSSG ratio in plasma; effects that were not seen in the healthy controls (10). The effect of prolonged oral GSH supplementation on skeletal muscle insulin sensitivity and mitochondrial ROS production in patients with T2D has, to our knowledge, never been investigated.
Research questions 1: Does oral GSH supplementation improve skeletal muscle insulin sensitivity in patients with T2D and healthy controls? And if so, can this effect be linked to a more beneficial redox state in the muscle cell? Hypothesis: Oral GSH supplementation will improve skeletal muscle insulin sensitivity in patients with T2D and this effect will be linked to a reduced mitochondrial ROS production in the skeletal muscle.
ROS production in response to acute exercise:
Acute exercise induces a marked increase in the transcription of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) (11), and therefore, PGC-1α is believed to play a key role in training-induced mitochondrial biogenesis (12). Contraction of rat skeletal muscle cells increases ROS production and PGC-1α mRNA expression, but in the presence of antioxidants, ROS production is reduced and the increase in PGC-1α mRNA is abolished (13). Also, exercise combined with allopurinol (an inhibitor of ROS production) severely attenuates the magnitude of the exercise-induced increased PGC-1α mRNA in rats, compared to exercise alone (14). These findings suggest that PGC-1α, at least in part, is regulated through a mechanism that involves ROS. Furthermore, it has been suggested that ROS regulates PGC-1α via activation of AMP-activated protein kinase (AMPK) (15). Interestingly, subjects with insulin resistance have a decreased exercise-stimulated AMPK activity, compared to lean controls (16, 17), which might explain the attenuated training-induced mitochondrial biogenesis observed in some patients with T2D (5, 17, 18), but not all (19). Whether ROS production is implicated in an abnormal training response is not known. Our current knowledge of ROS in response to acute exercise is derived from studies in animals and cells, and no study has, to our knowledge, investigated the link between ROS and mitochondrial biogenesis in patients with T2D in response to acute exercise.
Research questions 2: Does the exercise-induced increased ROS production required for a mitochondrial biogenesis response differ between patients with T2D and healthy controls? If so, does low intensity exercise reduce the transient ROS production and thus, result in a higher mitochondrial biogenesis response in patients with T2D, compared to exercise at high intensity? Hypothesis: Considering the pathological condition of T2D skeletal muscle (i.e. high chronic ROS level), it is hypothesized that a lower exercise intensity, leading to a lower exercise-stimulated ROS production is a more optimal stimulus (i.e. not to high) for mitochondrial biogenesis in patients with T2D.
Material and methodology:
20 patients with T2D (non-insulin dependent) and 20 healthy controls will be recruited to the study. The two groups will be matched on age, weight and maximal oxygen consumption (VO2 max).
Approach for the study: The study is a double blinded randomized placebo controlled trial.
At each attendance to the laboratory (except for the day of screening), the subjects are asked to:
Report to the laboratory in an overnight fasted state
Abstain from alcohol and physical activity 24 hours prior to each study day.
Repeat the same diet as the enclosed 24-hour recall questionnaire prescribes (the subjects are also asked to complete a 24-hour dietary recall questionnaire on their first attendance to the laboratory)
Screening: Before the subjects are included in the study, a standard clinical examination will be conducted, including medical history, glycated hemoglobin (HbA1c) and ECG.
If included in the study, the subjects undergoes 3 experimental days before and after the intervention.
Test day 1:
Dual Energy X-ray Absorptiometry-scan to measure body composition,
Incremental exercise test to determine the exercise intensity that elicits maximal fat oxidation (Fatmax test)
Incremental exercise test to exhaustion to determine VO2 max.
Test day 2:
Muscle biopsies from vastus lateralis (basal, immediately after exercise cessation and after 90 min of recovery)
Acute exercise tests on bicycle ergometers at 70% of VO2 max (moderate intensity) or at 50% of VO2 max (low intensity). The two exercise tests will be matched for total amount of work (kJ).
10 subjects with T2D and 10 control subjects are randomized to each exercise test.
Test day 3:
Measurement of resting metabolic rate by canopy hood (basal and during the clamp)
Intravenous glucose tolerance test
Hyperinsulinaemic euglycaemic clamp
After the experimental days, the subjects are randomized into placebo or GSH supplementation and instructed to consume either 1000 mg GSH/day or placebo daily (2 tablets in the morning and 2 tablets in the evening) for 4 weeks.
Statistical considerations:
The comparison of the groups or the interventions will be performed using a one-way or a two-way ANOVA test with repeated measures, as appropriate. Based on the variation shown in previous studies an expected 80% power and a significance level of P<0.05, power calculations have shown that 12 subjects in each group is sufficient in regards to mitochondrial functionality measurements and insulin sensitivity. Data from a previous study investigating GSH in healthy subjects indicates that 15 subjects are needed in order to find a difference in this parameter (3).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Oxidative Stress, Mitochondrial Reactive Oxygen Species Production
Keywords
type 2 diabetes, mitochondrial reactive oxygen species production, oxidative stress, antioxidant treatment, glutathione supplementation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
4 placebo tablets/day (2 in the morning and 2 in the evening)
Arm Title
Glutathione
Arm Type
Active Comparator
Arm Description
4 oral GSH tablets/day (2 in the morning and 2 in the evening)
Intervention Type
Dietary Supplement
Intervention Name(s)
Glutathione
Other Intervention Name(s)
Setria Glutathion
Intervention Description
4 oral GSH tablets/day (1000mg/day) for 4 weeks
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
4 oral placebo tablets for 4 weeks
Primary Outcome Measure Information:
Title
Insulin sensitivity
Description
Difference in insulin sensitivity (measured as glucose infusion rate during a hyperinsulinaemic euglycaemic clamp) between patients with type 2 diabetes receiving glutathione supplementation and patients with type 2 diabetes receiving placebo.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Mitochondrial reactive oxygen species production
Description
Difference in the mitochondrial reactive oxygen species production between patients with type 2 diabetes receiving glutathione supplementation and patients with type 2 diabetes receiving placebo.
Time Frame
12 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
For patients with type 2 diabetes:
Male
30-50 years
BMI: 28-35
ECG with no evidence of heart disease
HbA1c > 6.5% (48mmol/mol)
For control subjects:
Male
30-50 years
BMI: 28-35
ECG with no evidence of Heart disease
Exclusion Criteria:
For patients with type 2 diabetes::
Insulin treatment
Antioxidant supplementation or other dietary supplements
Cholesterol lowering medicine
For control subjects:
Antioxidant supplementation or other dietary supplements
Cholesterol lowering medicine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steen Larsen, Ass. prof.
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xlab, Department of Biomedical Sciences, Faculty Of Health Sciences, University of Copenhagen
City
Copenhagen
State/Province
Nørrebro
ZIP/Postal Code
2200
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
3289989
Citation
DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988 Jun;37(6):667-87. doi: 10.2337/diab.37.6.667. No abstract available.
Results Reference
background
PubMed Identifier
16612386
Citation
Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006 Apr 13;440(7086):944-8. doi: 10.1038/nature04634.
Results Reference
background
PubMed Identifier
19188683
Citation
Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009 Mar;119(3):573-81. doi: 10.1172/JCI37048. Epub 2009 Feb 2.
Results Reference
background
PubMed Identifier
19183935
Citation
Abdul-Ghani MA, Jani R, Chavez A, Molina-Carrion M, Tripathy D, Defronzo RA. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia. 2009 Apr;52(4):574-82. doi: 10.1007/s00125-009-1264-4. Epub 2009 Jan 30.
Results Reference
background
PubMed Identifier
20526759
Citation
Hey-Mogensen M, Hojlund K, Vind BF, Wang L, Dela F, Beck-Nielsen H, Fernstrom M, Sahlin K. Effect of physical training on mitochondrial respiration and reactive oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. Diabetologia. 2010 Sep;53(9):1976-85. doi: 10.1007/s00125-010-1813-x. Epub 2010 Jun 6.
Results Reference
background
PubMed Identifier
20382691
Citation
Chanseaume E, Barquissau V, Salles J, Aucouturier J, Patrac V, Giraudet C, Gryson C, Duche P, Boirie Y, Chardigny JM, Morio B. Muscle mitochondrial oxidative phosphorylation activity, but not content, is altered with abdominal obesity in sedentary men: synergism with changes in insulin sensitivity. J Clin Endocrinol Metab. 2010 Jun;95(6):2948-56. doi: 10.1210/jc.2009-1938. Epub 2010 Apr 9.
Results Reference
background
PubMed Identifier
19061483
Citation
Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009 Jan 1;417(1):1-13. doi: 10.1042/BJ20081386.
Results Reference
background
PubMed Identifier
24791752
Citation
Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015 Mar;54(2):251-63. doi: 10.1007/s00394-014-0706-z. Epub 2014 May 5.
Results Reference
background
PubMed Identifier
22186191
Citation
Calabrese V, Cornelius C, Leso V, Trovato-Salinaro A, Ventimiglia B, Cavallaro M, Scuto M, Rizza S, Zanoli L, Neri S, Castellino P. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta. 2012 May;1822(5):729-36. doi: 10.1016/j.bbadis.2011.12.003. Epub 2011 Dec 11.
Results Reference
background
PubMed Identifier
9711998
Citation
De Mattia G, Bravi MC, Laurenti O, Cassone-Faldetta M, Armiento A, Ferri C, Balsano F. Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998 Aug;47(8):993-7. doi: 10.1016/s0026-0495(98)90357-2.
Results Reference
background
PubMed Identifier
12563009
Citation
Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol. 2003 Feb 1;546(Pt 3):851-8. doi: 10.1113/jphysiol.2002.034850.
Results Reference
background
PubMed Identifier
11181630
Citation
Hood DA. Invited Review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol (1985). 2001 Mar;90(3):1137-57. doi: 10.1152/jappl.2001.90.3.1137.
Results Reference
background
PubMed Identifier
16916551
Citation
Silveira LR, Pilegaard H, Kusuhara K, Curi R, Hellsten Y. The contraction induced increase in gene expression of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator 1alpha (PGC-1alpha), mitochondrial uncoupling protein 3 (UCP3) and hexokinase II (HKII) in primary rat skeletal muscle cells is dependent on reactive oxygen species. Biochim Biophys Acta. 2006 Sep;1763(9):969-76. doi: 10.1016/j.bbamcr.2006.06.010. Epub 2006 Jul 7.
Results Reference
background
PubMed Identifier
19686839
Citation
Kang C, O'Moore KM, Dickman JR, Ji LL. Exercise activation of muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox sensitive. Free Radic Biol Med. 2009 Nov 15;47(10):1394-400. doi: 10.1016/j.freeradbiomed.2009.08.007. Epub 2009 Aug 14.
Results Reference
background
PubMed Identifier
19005163
Citation
Irrcher I, Ljubicic V, Hood DA. Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells. Am J Physiol Cell Physiol. 2009 Jan;296(1):C116-23. doi: 10.1152/ajpcell.00267.2007. Epub 2008 Nov 12.
Results Reference
background
PubMed Identifier
17327455
Citation
Sriwijitkamol A, Coletta DK, Wajcberg E, Balbontin GB, Reyna SM, Barrientes J, Eagan PA, Jenkinson CP, Cersosimo E, DeFronzo RA, Sakamoto K, Musi N. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes. 2007 Mar;56(3):836-48. doi: 10.2337/db06-1119.
Results Reference
background
PubMed Identifier
18182465
Citation
De Filippis E, Alvarez G, Berria R, Cusi K, Everman S, Meyer C, Mandarino LJ. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab. 2008 Mar;294(3):E607-14. doi: 10.1152/ajpendo.00729.2007. Epub 2008 Jan 8.
Results Reference
background
PubMed Identifier
14747278
Citation
Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes. 2004 Feb;53(2):294-305. doi: 10.2337/diabetes.53.2.294.
Results Reference
background
PubMed Identifier
20422397
Citation
Phielix E, Meex R, Moonen-Kornips E, Hesselink MK, Schrauwen P. Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individuals. Diabetologia. 2010 Aug;53(8):1714-21. doi: 10.1007/s00125-010-1764-2. Epub 2010 Apr 27.
Results Reference
background
PubMed Identifier
33740389
Citation
Sondergard SD, Cintin I, Kuhlman AB, Morville TH, Bergmann ML, Kjaer LK, Poulsen HE, Giustarini D, Rossi R, Dela F, Helge JW, Larsen S. The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial. Appl Physiol Nutr Metab. 2021 Sep;46(9):1133-1142. doi: 10.1139/apnm-2020-1099. Epub 2021 Mar 19.
Results Reference
derived
Learn more about this trial
The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise
We'll reach out to this number within 24 hrs